Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation (Q36607332)

15 August 2017

1 reference

title

Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation (English)

1 reference

15 August 2017

1 reference

Masato Asanuma

1

1 reference

PubMed ID

17009919

15 August 2017

Ikuko Miyazaki

series ordinal

2

1 reference

15 August 2017

1 September 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

9

1 reference

15 August 2017

1313-1325

1 reference

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Indomethacin reverses the microglial response to amyloid beta-protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Acetaminophen protects hippocampal neurons and PC12 cultures from amyloid beta-peptides induced oxidative stress and reduces NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Release of mediators of anaphylaxis: inhibition of prostaglandin synthesis and the modification of release of slow reacting substance of anaphylaxis and histamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal antiinflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Nitric oxide activates cyclooxygenase enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Inhibition of the induction of the inducible nitric oxide synthase in murine brain microglial cells by sodium salicylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Inhibition of NF-kappa B by sodium salicylate and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Nonsteroidal anti-inflammatory drugs inhibit expression of the inducible nitric oxide synthase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Synthesis of nitric oxide in CNS glial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Activation of nuclear factor kappaB by nitric oxide in rat striatal neurones: differential inhibition of the p50 and p65 subunits by dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

NF-kappa B: a crucial transcription factor for glial and neuronal cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Novel anti-inflammatory therapy for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Spatiotemporal induction patterns of cytokine and related immune signal molecule mRNAs in response to intrastriatal injection of lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Selective microglial activation in the rat rotenone model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine covalently modifies and functionally inactivates parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Intraneuronal dopamine-quinone synthesis: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Potential oxidative pathways of brain catecholamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Dopamine induces proteasome inhibition in neural PC12 cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Overexpression of Cu-Zn superoxide dismutase protects neuroblastoma cells against dopamine cytotoxicity accompanied by increase in their glutathione level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Increase of antioxidative potential by tert-butylhydroquinone protects against cell death associated with 6-hydroxydopamine-induced oxidative stress in neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

NSAIDs and incident Alzheimer’s disease. the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

21 January 2018

Towards a better aspirin

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.9.1313

10.1586/14737175.6.9.1313

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17009919